Cogstate Limited provided earnings guidance for the fiscal year 2021. The ongoing COVID pandemic creates a higher degree of uncertainty, particularly in respect to Clinical Trials revenue and therefore second half of 2021 earnings. Based on the assumption that the COVID pandemic does not materially impact the initiation of new clinical trials or the conduct of ongoing clinical trials over the balance of second half of 2021, the company is targeting positive profit before tax for fiscal year 2021.